Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hepatic Encephalopathy Clear all
Completed Phase 1 Interventional

Oral Fecal Transplant in Cirrhosis

NCT03152188
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
FMT, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jul 22, 2026, 11:55 AM EDT
Not yet recruiting Not applicable Interventional

Endoscopic Shunts Embolization for Refractory Hepatic Encephalopathy

NCT07553858
View directory record Official record
Conditions
Hepatic Encephalopathy, Liver Cirrhosis, Portal Shunt Systemic
Interventions
Endoscopic ultrasound-guided transgastric embolization of the spontaneous portosystemic shunts, Interventional Radiology for shunt embolization/retrograde tranvenous obliteration
Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 22, 2026, 11:55 AM EDT
Withdrawn Not applicable Interventional

Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)

NCT01923376
View directory record Official record
Conditions
Hepatic Encephalopathy, HE, Cirrhosis, Altered Mental Status, AMS
Interventions
Lactulose, Polyethylene Glycol 3350
Drug
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Not applicable Interventional Results available

Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.

NCT01283152
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Portosystemic Encephalopathy, PSE
Interventions
Polyethylene glycol 3350-electrolyte solution (GoLYTELY®), Lactulose
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Not applicable Interventional

A Study of Controlled Lactulose Withdrawal

NCT00914056
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
lactulose
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Jul 22, 2026, 11:55 AM EDT
Not listed No phase listed Observational

Flicker App for Minimal Hepatic Encephalopathy

NCT04415294
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Critical flicker frequency
Diagnostic Test
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Not applicable Interventional Results available

Rifaximin in Minimal Hepatic Encephalopathy

NCT00533910
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin, placebo
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Phase 2 Interventional

HEAL STUDY (Hepatic Encephalopathy and Albumin Study)

NCT03585257
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Covert Hepatic Encephalopathy
Interventions
25% IV albumin, Placebo
Biological · Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Jul 22, 2026, 11:55 AM EDT
Withdrawn No phase listed Observational

The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in Cirrhosis

NCT01777971
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Ascites, Fatigue
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Phase 2Phase 3 Interventional Results available

13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF

NCT02786836
View directory record Official record
Conditions
Acute Liver Failure
Interventions
13C-Methacetin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Rifaximin in Minimal Hepatic Encephalopathy

NCT01069133
View directory record Official record
Conditions
Minimal Hepatic Encephalopathy
Interventions
rifaximin
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Not applicable Interventional

CAREGIVER: A Trial to Improve the Burden and Distress of Caring for Persons With Decompensated Cirrhosis

NCT04205396
View directory record Official record
Conditions
Caregivers
Interventions
Written emotional disclosure, Resilience training, No treatment
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Jul 22, 2026, 11:55 AM EDT
Terminated Phase 4 Interventional

Quality of Life and Nutritional Improvements in Cirrhotic Patients

NCT01842113
View directory record Official record
Conditions
Liver Cirrhosis, Hepatic Encephalopathy, Portal Hypertension
Interventions
Rifaximin, Lactulose, Lactulose Placebo, Rifaximin Placebo
Drug
Lead sponsor
Tampa General Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Jul 22, 2026, 11:55 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS

NCT02048969
View directory record Official record
Conditions
Hepatic Encephalopathy, Liver Cirrhosis
Interventions
Flumazenil, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Jul 22, 2026, 11:55 AM EDT
Active, not recruiting Phase 2 Interventional

Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy

NCT03420482
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Fecal Microbiota Transplant (FMT) oral capsules, Placebo oral capsule
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Phase 1Phase 2 Interventional

Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy

NCT05070351
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
PPI deprescribing
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Jul 22, 2026, 11:55 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy

NCT04816916
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
AXA1665, Placebo
Drug
Lead sponsor
Axcella Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
21
States / cities
San Francisco, California • DeBary, Florida • Gainesville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Jul 22, 2026, 11:55 AM EDT
Enrolling by invitation No phase listed Observational

International Registry of Congenital Portosystemic Shunt (IRCPSS)

NCT06041906
View directory record Official record
Conditions
Congenital Portosystemic Shunt, CPSS (Congenital Portosystemic Shunt)
Interventions
Shunt Closure
Procedure
Lead sponsor
Prof. Valérie Mc Lin
Other
Eligibility
1 Day and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Phase 1 Interventional

Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy

NCT00992290
View directory record Official record
Conditions
Minimal Hepatic Encephalopathy
Interventions
Lactobacillus GG, Placebo
Biological
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Phase 3 Interventional Results available

N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure

NCT00248625
View directory record Official record
Conditions
Acute Liver Failure, Hepatic Encephalopathy
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 18 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Jul 22, 2026, 11:55 AM EDT
Completed No phase listed Observational

Autoregulation Assessment During Liver Transplantation

NCT01425385
View directory record Official record
Conditions
Liver Failure, Liver Transplantation, Encephalopathy
Interventions
Near infrared spectroscopy monitoring, Autoregulation monitoring
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Jul 22, 2026, 11:55 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Factors Associated With End Stage Liver Disease

NCT01846819
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Fatigue, Depression
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Phase 2 Interventional Results available

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

NCT01966419
View directory record Official record
Conditions
Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Interventions
ornithine phenylacetate, placebo intravenous infusion
Drug
Lead sponsor
Ocera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Jul 22, 2026, 11:55 AM EDT
Not listed Phase 2 Interventional

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy

NCT00281502
View directory record Official record
Conditions
Hepatic Encephalopathy, Hepatitis C, Liver Cirrhosis
Interventions
Rifaximin (drug)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2010 · Synced Jul 22, 2026, 11:55 AM EDT